Aiosyn has announced the release of an artificial intelligence (AI) kidney suite designed to advance research in the field of renal disease.
Leveraging deep-learning technology, the solution provides biopharma and research organisations with tools for analysing kidney structures and quantifying lesions that impact kidney health. Aiosyn’s kidney AI suite marks another milestone for the company, following the recent launch of Aiosyn Mitosis Research.
Patrick de Boer, CEO of Aiosyn, said: “The platform will enable researchers to identify new and existing chronic kidney disease (CKD) biomarkers to study specific patient subgroups. With these new algorithms and AI capabilities we provide CKD researchers with new tools to complement existing biomarker projects and help to advance CKD precision medicine.”
Aiosyn’s kidney AI suite utilises AI-powered computational pathology algorithms to objectively quantify kidney lesion scores, offering an opportunity to enhance reproducibility and accelerate drug development. The platform addresses the limitations of the Banff classification currently used in renal biopsy analysis, which suffers from observer variability and relies on qualitative assessments.
Aiosyn’s kidney AI suite facilitates the identification and characterisation of pathological processes, presenting a promising avenue for substantial improvements in CKD research and clinical trials. Alongside its kidney AI platform, Aiosyn is actively developing advanced deep learning algorithms for the detection of cancer biomarkers.
